Lowenstein represented Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP), a clinical-stage biopharmaceutical company, in its $25 million acquisition of two currently-marketed products, Sembrace® SymTouch® (sumatriptan injection) 3 mg and Tosymra® (sumatriptan nasal spray) 10 mg, from Upsher-Smith Laboratories, LLC.
Zembrace SymTouch and Tosymra are both indicated for the treatment of acute migraine with or without aura in adults. Nearly 40 million people in the United States suffer from migraine and it has been recognized as the second leading cause of disability in the world.
Tonix is a clinical-stage biopharmaceutical company focused on discovering, licensing, acquiring and developing therapeutics to treat and prevent human disease and alleviate suffering. Tonix’s portfolio is composed of central nervous system (CNS), rare disease, immunology, and infectious disease product candidates. Lowenstein previously represented Tonix in its recent acquisitions of Healion Bio, Inc. and a research and development center focused on developing vaccines for covid-19 and other infectious diseases.
The Lowenstein deal team included Michael J. Lerner, Nicholas G. Mehler, Robert J. Paradiso, Sophia Mokotoff, Irina Ishak, James C. Shehan, James Assmann, Oluwaseyi O. Amorin, Nathaniel A. Perle, and Jenna-Marie Tracy.